Disparate effects of atorvastatin compared with simvastatin on C-reactive protein concentrations in patients with type 2 diabetes

Thozhukat Sathyapalan, Stephen Atkin, Eric S. Kilpatrick

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

OBJECTIVE - Reduction in LDL and high sensitivity (hs) C-reactive protein (CRP) are independent indicators of successful cardiovascular risk reduction with statins. This study compared the effect of equivalent LDL-lowering doses of simvastatin and atorvastatin on hsCRP in type 2 diabetic patients. RESEARCH DESIGN AND METHODS - A crossover study of 26 patients with type 2 diabetes taking either 40 mg simvastatin or 10 mg atorvastatin was undertaken. After 3 months on one statin, lipids and hsCRP were measured on 10 occasions over a 5-week period. The same procedure was then followed taking the other statin. RESULTS - LDL was comparable on either treatment: atorvastatin 2.2 ± 0.2 vs. 2.1 ± 0.3 mmol/l (mean ± SD; P = 0.19). CRP of individuals taking atorvastatin was significantly lower than when they were taking simvastatin (median 1.08 vs. 1.47 mg/l, P = 0.0002) and was less variable (median SD of logCRP 0.0036 vs. 0.178, P = 0.0001). CONCLUSIONS - Compared with simvastatin, atorvastatin reduced hsCRP and its variability in type 2 diabetic patients. This enhanced anti-inflammatory effect may prove beneficial if lower CRP is associated with improved cardiovascular risk.

Original languageEnglish
Pages (from-to)1948-1950
Number of pages3
JournalDiabetes Care
Volume33
Issue number9
DOIs
Publication statusPublished - Sep 2010
Externally publishedYes

Fingerprint

Simvastatin
C-Reactive Protein
Type 2 Diabetes Mellitus
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Risk Reduction Behavior
Cross-Over Studies
Anti-Inflammatory Agents
Research Design
Atorvastatin Calcium
Lipids

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialised Nursing

Cite this

Disparate effects of atorvastatin compared with simvastatin on C-reactive protein concentrations in patients with type 2 diabetes. / Sathyapalan, Thozhukat; Atkin, Stephen; Kilpatrick, Eric S.

In: Diabetes Care, Vol. 33, No. 9, 09.2010, p. 1948-1950.

Research output: Contribution to journalArticle

@article{1deba6cc800e49ca91308a3238b3d653,
title = "Disparate effects of atorvastatin compared with simvastatin on C-reactive protein concentrations in patients with type 2 diabetes",
abstract = "OBJECTIVE - Reduction in LDL and high sensitivity (hs) C-reactive protein (CRP) are independent indicators of successful cardiovascular risk reduction with statins. This study compared the effect of equivalent LDL-lowering doses of simvastatin and atorvastatin on hsCRP in type 2 diabetic patients. RESEARCH DESIGN AND METHODS - A crossover study of 26 patients with type 2 diabetes taking either 40 mg simvastatin or 10 mg atorvastatin was undertaken. After 3 months on one statin, lipids and hsCRP were measured on 10 occasions over a 5-week period. The same procedure was then followed taking the other statin. RESULTS - LDL was comparable on either treatment: atorvastatin 2.2 ± 0.2 vs. 2.1 ± 0.3 mmol/l (mean ± SD; P = 0.19). CRP of individuals taking atorvastatin was significantly lower than when they were taking simvastatin (median 1.08 vs. 1.47 mg/l, P = 0.0002) and was less variable (median SD of logCRP 0.0036 vs. 0.178, P = 0.0001). CONCLUSIONS - Compared with simvastatin, atorvastatin reduced hsCRP and its variability in type 2 diabetic patients. This enhanced anti-inflammatory effect may prove beneficial if lower CRP is associated with improved cardiovascular risk.",
author = "Thozhukat Sathyapalan and Stephen Atkin and Kilpatrick, {Eric S.}",
year = "2010",
month = "9",
doi = "10.2337/dc10-0201",
language = "English",
volume = "33",
pages = "1948--1950",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "9",

}

TY - JOUR

T1 - Disparate effects of atorvastatin compared with simvastatin on C-reactive protein concentrations in patients with type 2 diabetes

AU - Sathyapalan, Thozhukat

AU - Atkin, Stephen

AU - Kilpatrick, Eric S.

PY - 2010/9

Y1 - 2010/9

N2 - OBJECTIVE - Reduction in LDL and high sensitivity (hs) C-reactive protein (CRP) are independent indicators of successful cardiovascular risk reduction with statins. This study compared the effect of equivalent LDL-lowering doses of simvastatin and atorvastatin on hsCRP in type 2 diabetic patients. RESEARCH DESIGN AND METHODS - A crossover study of 26 patients with type 2 diabetes taking either 40 mg simvastatin or 10 mg atorvastatin was undertaken. After 3 months on one statin, lipids and hsCRP were measured on 10 occasions over a 5-week period. The same procedure was then followed taking the other statin. RESULTS - LDL was comparable on either treatment: atorvastatin 2.2 ± 0.2 vs. 2.1 ± 0.3 mmol/l (mean ± SD; P = 0.19). CRP of individuals taking atorvastatin was significantly lower than when they were taking simvastatin (median 1.08 vs. 1.47 mg/l, P = 0.0002) and was less variable (median SD of logCRP 0.0036 vs. 0.178, P = 0.0001). CONCLUSIONS - Compared with simvastatin, atorvastatin reduced hsCRP and its variability in type 2 diabetic patients. This enhanced anti-inflammatory effect may prove beneficial if lower CRP is associated with improved cardiovascular risk.

AB - OBJECTIVE - Reduction in LDL and high sensitivity (hs) C-reactive protein (CRP) are independent indicators of successful cardiovascular risk reduction with statins. This study compared the effect of equivalent LDL-lowering doses of simvastatin and atorvastatin on hsCRP in type 2 diabetic patients. RESEARCH DESIGN AND METHODS - A crossover study of 26 patients with type 2 diabetes taking either 40 mg simvastatin or 10 mg atorvastatin was undertaken. After 3 months on one statin, lipids and hsCRP were measured on 10 occasions over a 5-week period. The same procedure was then followed taking the other statin. RESULTS - LDL was comparable on either treatment: atorvastatin 2.2 ± 0.2 vs. 2.1 ± 0.3 mmol/l (mean ± SD; P = 0.19). CRP of individuals taking atorvastatin was significantly lower than when they were taking simvastatin (median 1.08 vs. 1.47 mg/l, P = 0.0002) and was less variable (median SD of logCRP 0.0036 vs. 0.178, P = 0.0001). CONCLUSIONS - Compared with simvastatin, atorvastatin reduced hsCRP and its variability in type 2 diabetic patients. This enhanced anti-inflammatory effect may prove beneficial if lower CRP is associated with improved cardiovascular risk.

UR - http://www.scopus.com/inward/record.url?scp=78649922807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649922807&partnerID=8YFLogxK

U2 - 10.2337/dc10-0201

DO - 10.2337/dc10-0201

M3 - Article

C2 - 20805273

AN - SCOPUS:78649922807

VL - 33

SP - 1948

EP - 1950

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 9

ER -